Test description
Testing of a broad panel of genes associated with inherited cancer predisposition across multiple organ systems.
Test information
BRAoVO™ Pan Cancer gene panel
Testing for patients with complex, early‑onset, or multi‑system cancer histories where a broad hereditary cancer assessment is required. Results may assist in identifying inherited cancer risk, guiding clinical management, and informing surveillance and family testing.
AIP, APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A,CHEK2, CTNNA1, DICER1, EPCAM, FH, FLCN, GREM1, HOXB13, KIT, LZTR1, MAX, MEN1, MET, MITF, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PMS2, PMS2CL, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51C, RAD51D, RB1, RET, RNF43, SCG5, SDHA, SDHAF2, SDHB, SDHC, SDHD, SEC23B, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WRN, WT1
Massively Parallel Sequencing
6 weeks
$950 if not Medicare eligible
Cancer Genetics Request form preferred. Standard pathology request form accepted.
Blood x 2
EDTA
2 x Bloods taken at 10 minute intervals. Pre-test genetic counselling required. Patient to sign a consent form prior to testing, which stays with the specialist.